News
SYBX
0.621
-12.61%
-0.090
Weekly Report: what happened at SYBX last week (0615-0619)?
Weekly Report · 1d ago
Weekly Report: what happened at SYBX last week (0608-0612)?
Weekly Report · 06/15 09:03
Weekly Report: what happened at SYBX last week (0601-0605)?
Weekly Report · 06/08 09:02
Weekly Report: what happened at SYBX last week (0525-0529)?
Weekly Report · 06/01 09:03
Weekly Report: what happened at SYBX last week (0518-0522)?
Weekly Report · 05/25 09:03
Weekly Report: what happened at SYBX last week (0511-0515)?
Weekly Report · 05/18 09:03
Weekly Report: what happened at SYBX last week (0504-0508)?
Weekly Report · 05/11 09:03
Weekly Report: what happened at SYBX last week (0427-0501)?
Weekly Report · 05/04 09:02
Weekly Report: what happened at SYBX last week (0420-0424)?
Weekly Report · 04/27 09:03
Weekly Report: what happened at SYBX last week (0413-0417)?
Weekly Report · 04/20 09:02
Weekly Report: what happened at SYBX last week (0406-0410)?
Weekly Report · 04/13 09:03
Weekly Report: what happened at SYBX last week (0330-0403)?
Weekly Report · 04/06 09:03
Weekly Report: what happened at SYBX last week (0323-0327)?
Weekly Report · 03/30 09:03
Weekly Report: what happened at SYBX last week (0316-0320)?
Weekly Report · 03/23 09:02
Weekly Report: what happened at SYBX last week (0309-0313)?
Weekly Report · 03/16 09:02
Weekly Report: what happened at SYBX last week (0302-0306)?
Weekly Report · 03/09 09:02
Weekly Report: what happened at SYBX last week (0223-0227)?
Weekly Report · 03/02 09:02
Weekly Report: what happened at SYBX last week (0216-0220)?
Weekly Report · 02/23 09:02
Weekly Report: what happened at SYBX last week (0209-0213)?
Weekly Report · 02/16 09:02
Weekly Report: what happened at SYBX last week (0202-0206)?
Weekly Report · 02/09 09:03
More
Webull provides a variety of real-time SYBX stock news. You can receive the latest news about Synlogic through multiple platforms. This information may help you make smarter investment decisions.
About SYBX
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.